1. Home
  2. HLI vs IMVT Comparison

HLI vs IMVT Comparison

Compare HLI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Houlihan Lokey Inc.

HLI

Houlihan Lokey Inc.

HOLD

Current Price

$129.05

Market Cap

9.7B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$44.37

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLI
IMVT
Founded
1972
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
8.5B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
HLI
IMVT
Price
$129.05
$44.37
Analyst Decision
Buy
Buy
Analyst Count
7
8
Target Price
$194.29
$33.00
AVG Volume (30 Days)
932.4K
1.0M
Earning Date
05-06-2026
05-28-2026
Dividend Yield
1.54%
N/A
EPS Growth
6.87
N/A
EPS
1.15
N/A
Revenue
$2,617,516,000.00
N/A
Revenue This Year
$13.77
N/A
Revenue Next Year
$12.10
N/A
P/E Ratio
$111.36
N/A
Revenue Growth
9.55
N/A
52 Week Low
$112.83
$14.47
52 Week High
$211.78
$45.42

Technical Indicators

Market Signals
Indicator
HLI
IMVT
Relative Strength Index (RSI) 47.00 67.95
Support Level $112.83 $37.16
Resistance Level $144.92 N/A
Average True Range (ATR) 4.40 1.47
MACD 0.47 0.34
Stochastic Oscillator 58.31 83.53

Price Performance

Historical Comparison
HLI
IMVT

About HLI Houlihan Lokey Inc.

Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: